|
Situation
|
Infection, encrustation and blockage of long-term indwelling catheters, ureteral stents and nephrostomy tubes are significant medical and health-economic problems. Because of these problems, about 50% of patients with permanent urinary drainage devices present as emergency cases during their course of disease, 13000 patients die and up to 1.3 Billion Euro additional costs are produced per year in Western Europe and a similar amount in North America.
Source: Riedl CR, International Journal of Antimicrobial Agents; Klevens RM, Public Health Reports |
Challenge |
|
Commonly urinary tract infections are treated with antibiotics. But the wide use of antibiotic medication harbours the risk of promoting bacterial resistances. Resistant bacteria can't be effectively treated by antibiotics anymore to help critically ill patients.
To use coated stents and catheters is another approach. But most of those devices face the same problems: Antibiotic, silver and other biozide coatings also lead to resistances. |
Breakthrough
|
|
UroNova's unique patented technology protects stents and catheters from bacterial biofilm formation and subsequent encrustation without using antibioctics, silver particels or any other biozide substance. Proven, hundred-thousandfold in clinical every-day practice.
No drug elution takes place, so no systemic side effects are caused. The coating's effectiveness is not limited in time, as it is long-term stable. Biocompatibility is unparalleled. |